LLY
742.34
+2.24%↑
UNH
524.47
+2.96%↑
JNJ
148.01
+0.7%↑
ABBV
172.39
+0.6%↑
NVO
80.97
+2.85%↑
LLY
742.34
+2.24%↑
UNH
524.47
+2.96%↑
JNJ
148.01
+0.7%↑
ABBV
172.39
+0.6%↑
NVO
80.97
+2.85%↑
LLY
742.34
+2.24%↑
UNH
524.47
+2.96%↑
JNJ
148.01
+0.7%↑
ABBV
172.39
+0.6%↑
NVO
80.97
+2.85%↑
LLY
742.34
+2.24%↑
UNH
524.47
+2.96%↑
JNJ
148.01
+0.7%↑
ABBV
172.39
+0.6%↑
NVO
80.97
+2.85%↑
LLY
742.34
+2.24%↑
UNH
524.47
+2.96%↑
JNJ
148.01
+0.7%↑
ABBV
172.39
+0.6%↑
NVO
80.97
+2.85%↑
24h
Current
Min
66.5
Max
66.8
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +33.15 upside |
By Trading Central
Confidence
Very Strong Bullish Evidence
65.64 / 66.61 Support & Resistance
Past performance is not a reliable indicator of future results.
24 Dec 2024, 15:24 UTC
Achilles Therapeutics Sells Technology Assets to AstraZeneca for $12 Million
DJ
Read
12 Nov 2024, 19:55 UTC
AstraZeneca Expands U.S. Investment Plan -- 3rd Update
DJ
Read
12 Nov 2024, 11:02 UTC
AstraZeneca Raises Outlook, Plans U.S. Investment -- Update
DJ
Read
12 Nov 2024, 07:37 UTC
AstraZeneca Raises Outlook on Earnings, Sales Beat
DJ
Read
20 Jan 2025, 08:02 UTC
AstraZeneca Trial Results In Focus Amid China Sales Concerns -- Market Talk
DJ
Read
18 Nov 2024, 10:33 UTC
Pharmaceutical Sector Outlook for 2025 Looks Rocky -- Market Talk
DJ
Read
15 Nov 2024, 13:08 UTC
Trump's RFK Pick Weighs on Vaccine Makers -- WSJ
DJ
Read
15 Nov 2024, 10:29 UTC
Stocks to Watch Friday: Tesla, Domino's, Palantir, Ulta -- WSJ
DJ
Read
12 Nov 2024, 15:30 UTC
AstraZeneca Expands U.S. Investment Plan -- 2nd Update
DJ
Read
12 Nov 2024, 13:39 UTC
AstraZeneca's Results Make $80B Revenue Target Look Achievable -- Market Talk
DJ
Read
12 Nov 2024, 10:49 UTC
AstraZeneca Seen With Positive Momentum at Pivotal Period -- Market Talk
DJ
Read
12 Nov 2024, 09:52 UTC
AstraZeneca's New Guidance Could Imply Consensus Upgrades -- Market Talk
DJ
Read
12 Nov 2024, 07:02 UTC
AstraZeneca Had Seen 2024 Core EPS Growth by Mid Teens Percentage Range
DJ
Read
12 Nov 2024, 07:02 UTC
AstraZeneca Sees 2024 Core EPS Growth In High Teens Percentage Range
DJ
Read
12 Nov 2024, 07:02 UTC
AstraZeneca Had Seen 2024 Total Revenue Growth In Mid Teens Percentage Range
DJ
Read
12 Nov 2024, 07:02 UTC
AstraZeneca Sees 2024 Total Revenue Growth In High Teens Percentage Range
DJ
Read
12 Nov 2024, 07:02 UTC
AstraZeneca Raises 2024 View
DJ
Read
12 Nov 2024, 07:01 UTC
Analysts Saw AstraZeneca 3Q Sales at $13.1B
DJ
Read
12 Nov 2024, 07:01 UTC
Analysts Saw AstraZeneca 3Q Core EPS at $2.04
DJ
Read
12 Nov 2024, 07:00 UTC
AstraZeneca PLC 3Q EPS 91c
DJ
Read
12 Nov 2024, 07:00 UTC
AstraZeneca PLC 3Q Net Pft $1.43B
DJ
Read
12 Nov 2024, 07:00 UTC
AstraZeneca PLC 3Q Oper Pft $2.11B
DJ
Read
7 Nov 2024, 08:03 UTC
China Has Detained a Senior AstraZeneca Executive -- Update
DJ
Read
6 Nov 2024, 18:55 UTC
China Has Detained Senior AstraZeneca Executive -- WSJ
DJ
Read
1 Nov 2024, 03:00 UTC
U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ
DJ
Read
31 Oct 2024, 19:48 UTC
AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- Update
DJ
Read
31 Oct 2024, 14:43 UTC
AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- WSJ
DJ
Read
12 Sept 2024, 17:01 UTC
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update
DJ
Read
12 Sept 2024, 11:00 UTC
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
DJ
Read
10 Sept 2024, 13:08 UTC
AstraZeneca's Lung Cancer Drug Candidate Disappoints, Lowering Probability of FDA Approval -- Market Talk
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 88.68 USD 33.15%
High 91.7 USD
Low 87 USD
Based on 5 Wall Street analysts offering 12 month price targets forAstraZeneca PLC ADR - Dist in the last 3 months.
By TipRanks
Strong Buy
5 ratings
5
Buy
0
Hold
0
Sell
Based on 5 analysts giving stock ratings to AstraZeneca PLC ADR - Dist in the past 3 months.
By Trading Central
Short Term
Very Strong Bullish Evidence
Recent bullish events outweigh bearish events.
Intermediate Term
Weak Bearish Evidence
Recent bearish events outweigh bullish events.
Long Term
Weak Bearish Evidence
Bearish events outweigh bullish events.
$